{"iri":"http://lmss.sali.org/RCsgBzhoO77TRUSo5O757qS","id":"RCsgBzhoO77TRUSo5O757qS","label":"Abbreviated New Drug Application Claim","definition":"An Abbreviated New Drug Application (ANDA) Claim arises when there is a dispute or legal challenge related to the submission or approval of an ANDA, which allows for the marketing of a generic drug that demonstrates bioequivalence to an already approved brand-name drug. This claim can involve issues of patent infringement, exclusivity rights, or regulatory compliance.","prefLabels":["ANDA Claim"],"altLabels":["ANDA Dispute Claim","Bioequivalence Application Claim","Generic Drug Application Claim","Generic Medicine Application Claim"],"examples":[],"notes":[],"sources":[],"branch":{"iri":"http://lmss.sali.org/RlNFgB3TQfMzV26V4V7u4E","label":"Objectives"},"parents":[{"iri":"http://lmss.sali.org/R9LVBKjvGRuzwgtlhuLST36","id":"R9LVBKjvGRuzwgtlhuLST36","label":"Statutory and Regulatory Claims"},{"iri":"http://lmss.sali.org/RJL4HDUmZp1VEEZ7lCwSSF","id":"RJL4HDUmZp1VEEZ7lCwSSF","label":"Intellectual Property Claims"}],"children":[],"relations":[],"url":"https://lmss.io/tag/RCsgBzhoO77TRUSo5O757qS/","source":{"repo":"sali-legal/LMSS","ref":"3f9ac0c9357b2a971582ae79ede243511d47811d","channel":"pre-release"}}